Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Advances in the Treatment of Renal Cell Carcinoma
| Advances in the Treatment of Renal Cell Carcinoma |
| Autore | Reynolds Paul |
| Pubbl/distr/stampa | Basel, : MDPI - Multidisciplinary Digital Publishing Institute, 2022 |
| Descrizione fisica | 1 electronic resource (221 p.) |
| Soggetto topico | Medicine |
| Soggetto non controllato |
renal cell carcinoma
autophagy hydroxychloroquine chloroquine ROC-325 cysteine cathepsins cysteine cathepsin inhibitors lysosome renal cancer metastatic renal cell carcinoma immune-based combination therapies network meta-analysis PD-L1 predictive biomarker treatment TKIs mRCC biomarkers soluble factors immunotherapy renal cell carcinoma (RCC) sunitib resistance artesunate (ART) Traditional Chinese Medicine (TCM) growth inhibition ferroptosis reactive oxygen species (ROS) clear cell renal cell carcinoma ccRCC RCC kidney cancer evolution evolutionary trajectory metastatic second line therapy renal cell cancer immune checkpoint inhibitors tyrosine kinase inhibitors individualization genomic signature transcriptomic analysis |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910557615503321 |
Reynolds Paul
|
||
| Basel, : MDPI - Multidisciplinary Digital Publishing Institute, 2022 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
New Therapies of Liver Diseases
| New Therapies of Liver Diseases |
| Autore | Toniutto Pierluigi |
| Pubbl/distr/stampa | Basel, : MDPI - Multidisciplinary Digital Publishing Institute, 2022 |
| Descrizione fisica | 1 electronic resource (236 p.) |
| Soggetto topico | Public health & preventive medicine |
| Soggetto non controllato |
tolvaptan
cirrhotic ascites survival rate furosemide primary biliary cholangitis autoantibodies ursodeoxycholic acid treatment response second line therapy primary biliary cholangitis (PBC) primary sclerosing cholangitis (PSC) clinical trials ursodeoxycholic acid (UDCA) Farnesoid X Receptor (FXR) agonist Pan-Peroxisome Proliferator-Activated Receptor (PPAR) agonists liver cancer systemic treatment immunotherapy real-world unresectable hepatocellular carcinoma cirrhosis decompensation bleeding varices survival infection alcoholic hepatitis acute-on-chronic liver failure cholangiocarcinoma colorectal cancer metastases hepatocellular carcinoma liver transplantation Milan criteria alpha-fetoprotein solid organ transplantation liver injury immunosuppressant SARS-CoV-2 humoral response vaccination portal-systemic shunt ammonia vigilance HBV HDV antivirals functional cure pharmacology acute-on-chronic liver failure (ACLF) liver transplantation (LT) decompensated cirrhosis portal hypertension ascites non-selective beta-blockers TIPS rifaximin human albumin statins targeted therapy effective hypovolemia anti-mineralocorticoids loop diuretics vaptans |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910566457403321 |
|
Toniutto Pierluigi
|
||
| Basel, : MDPI - Multidisciplinary Digital Publishing Institute, 2022 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||